Like Biodefense Stocks? View our Biodefense Stocks Directory
Breaking Tech News: NXT-ID (NasdaqCM: NXTD) Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology
Cyber Security Stock Rapid7 (NASDAQ:RPD) Soars on Market Debut
NXT-ID (NASDAQ:NXTD) Media Alert: Recent News of Behavior-Directed Payments Patent has Payment Media Outlets Taking Notice
Research and Markets: Biometrics for Banking - Market & Technology Analysis, Adoption Strategies and Forecasts 2015-2020
Research and Markets: Fingerprint Biometrics - Global Strategic Business Report 2015 with Recent Industry Activity for All Key Players
View Systems, Inc. (VSYM) Continues Nationwide Installation of its Weapons Detection Technology
Biometrics to become the predominant method to identify bank customers by 2020
Breaking Tech News: NXT-ID, Inc. (Nasdaq:NXTD; NXTDW) to Air New Video on CNBC in New York Markets
Breaking Tech News: NXT-ID, Inc. (Nasdaq:NXTD; NXTDW) Announces Participation as Member of Team Battelle for TIES Contract Award
Breaking Tech News: NXT-ID, Inc.'s (NASDAQ:NXTD) (NXTDW) CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC.
Soligenix Enters into a $10 Million Equity Purchase Agreement
3, 2015 /PRNewswire/ -- Soligenix, Inc. (otcqb:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it ...
Soligenix Inc (OTCBB:SNGX) Finalizes A $10 Million Equity Purchase Deal
Penny Stocks Active Momentum:Soligenix (SNGX), Alpha Natural (ANRZ), South32 ...
Luminex Upgraded to Outperform by Wedbush (LMNX)
Dakota Financial News
In other Luminex news, CEO Nachum Shamir purchased 6,000 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average price of $16.73 per share, with a total value of ... The Company's xMAP (NASDAQ ...
Luminex Corporation (LMNX:NASDAQ) Analyst Price Target Update
Luminex (LMNX) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS
Company Shares of Luminex Corporation Drops by -2.38%
Zacks Lowers Alexandria Real Estate Equities to Hold (ARE)
Dakota Financial News
Our properties are designed and improved for lease primarily to institutional, pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational medicine entities, as well as governmental agencies. “ Other ...
Aeolus Pharmaceuticals, Inc ( OTC:AOLS ) is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.
Aethlon Medical, Inc. ( NasdaqCM:AEMD ) Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression.
Alexium International Group ( ASX:AJX.AX ) is engaged in developing and licensing its intellectual property, Reactive Surface Treatment (RST) technology. Alexium is focused on developing the RST technology for a range of military and commercial applications. Alexium's Reactive Surface Treatment (RST) is a technology for nanoscopic coatings that combines advanced materials chemistry with a processing step. Alexium's Reactive Surface Treatment (RST) uses cold microwave energy to direct a precursor's polymerization onto a substrate's surface. Its technology is used in textiles, air/fluid filtration, industrial coatings, composite fibers, leather, glass/lens surface treatment, bulk chemicals and thin films. BIODEFENSE: Responding to specific military and first responder needs, Alexium developed the Cleanshell® chemistry to offer a new generation of liquid repellency protection in chemical and biological threat scenarios. Cleanshell® CB is an advanced repellency treatment, optimized for chemical and biological protection. Cleanshell® CB has been optimized to provide excellent water and oil repellency, but has also dramatically increased the repellency of Chemical Warfare Agent (CWA) simulants. Cleanshell® CB offers days of protection versus minutes for conventional fluorocarbon repellency finishes.
American Science and Engineering, Inc ( NasdaqGS: ASEI ) is a leading worldwide supplier of innovative X-ray inspection systems. With over 50 years of experience in developing advanced X-ray security systems, the Company's product line utilizes a combination of technologies, including patented Z Backscatter™ technology, Radioactive Threat Detection (RTD), high energy transmission and dual energy transmission X-ray. These technologies offer superior X-ray threat detection for plastic explosives, plastic weapons, liquid explosives, dirty bombs and nuclear devices. AS&E's complete range of products include cargo inspection systems for port and border security baggage screening systems for facility and aviation security, and personnel and passenger screening systems. AS&E® systems protect high-threat facilities and help combat terrorism, trade fraud, drug smuggling, weapon smuggling, illegal immigration, and people smuggling.
BRUKER Corporation ( NasdaqGS: BRKR ) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. CBRN (Chemical, biological, radiological, and nuclear defense) : The CBRNE threats facing Armed Forces, Emergency and Security Services across the globe are complex. Simple and reliable solutions are required in order to provide protection and fast, effective response. As the market leader in CBRNE for over 20 years, Bruker understand the threat and needs of those operating against it. Our trusted equipment and software is installed around the world providing unrivalled protection. Our equipment is always easy to use and enables full spectrum Detection, Identification and Monitoring utilising state of the art technology.
Cepheid ( NasdaqGS: CPHD ) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. BIOTHREATS : The Cepheid GeneXpert® System makes biothreat agent detection possible in minutes — all from unprepared samples. This easy-to-use, automated and highly accurate real-time PCR instrument combines the ingenuity of more than 30 patents into a sophisticated genetic tool for first responders. A patented, disposable, cartridge test for anthrax is available now, and can be performed on-site — delivering critical answers in critical situations.
Cleveland BioLabs, Inc. ( NasdaqCM:CBLI ) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. BIODEFENSE:Entolimod (CBLB502) Biodefense
Dynasil Corporation of America ( NasdaqGM:DYSL ) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets. Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing.
Electronic Sensor Technology ( OTC:ESNR) develops, manufactures, and sells electronic devices used for vapor analysis. The company offers zNose, an electronic nose designed for various industry applications, which can detect odors and chemical vapors produced by explosives, chemicals, and biological weapons, as well as used for identifying hazardous industrial materials, improvised explosives, and flammable materials. Its product is used in the homeland security, chemical and petrochemical, environmental, life science, and food and beverage industries. The company also provides spare parts, such as columns, saw detectors, and traps; and accessories, including rugged shipping case, battery assemblies, battery chargers, DC/AC inverters, desorbers, heaters, remote samplers, sample injectors, system controllers, user tool kits, and water traps, as well as support and validation services. Electronic Sensor Technology offers its products through online store.
Emergent BioSolutions, Inc. ( NYSE:EBS ) is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company provides the world's only FDA-licensed anthrax vaccine to protect against anthrax disease, BioThrax®.See the full stock directory here